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Abstract
About 2–3 % of the population and about 35–50 % of people over 65 years suffer from obliterating atherosclerosis of the main 
arteries of the lower extremities. There are many known factors that potentiate atherosclerosis. Some of them are referred to as leading, 
such as hyperlipoproteinemia or hypertension, others to concomitant contributing to the defeat of the arteries. According to J.S.A. Fuchs 
include hypertension, hypercholesterolemia and smoking as major risk factors for atherosclerosis. They are less affected by obesity, 
diabetes, hypertriglyceridemia, sedentary lifestyle, stress
Objective of the study. The purpose of this study is to evaluate the functional status of the vascular – platelet, coagulation and 
fibrinolysis of the hemostasis system and their disorders using low – frequency piezoelectric thromboelastography (LPTEG) in patients 
with obliterating atherosclerosis of the lower extremities on the background of treatment.
Materials and methods. The initial state of the hemostasis system was evaluated in 90 patients undergoing treatment for 
obliterating atherosclerosis of the lower extremities in the Odessa Regional Clinical Hospital and MD Odreks. All patients underwent 
surgery in the amount of femoral-popliteal autologous bypass grafting. Patients in the control (1st) group (45 patients) received analgesia 
during surgery and in the postoperative period based on epidural administration of bupivacaine, and their treatment regimen included 
enoxaparin 0.4 ml (40,000 anti-XA ME) 2 times a day subcutaneously into the anterolateral surface of the abdominal wall from the 
first postoperative day and pentoxifylline IV 200 mg twice a day for 7 days. Patients of the studied (2nd) group (45 patients) received 
analgesia during surgery and in the postoperative period on the basis of epidural administration of bupivacaine, also rivaroxaban 15 mg 
2 times a day oraly on the first postoperative day was included in their treatment regimen.
The dynamics of the state of the hemostatic system in both groups of patients with OA was evaluated using LPTEG in the first 
day before surgery and on the 3rd, 5th and 7th postoperative days.
Results and conclusions. Before surgery and the start of treatment in patients with OA, against the background of activation of 
the vascular - platelet link of hemostasis, significant structural and chronometric hypercoagulation with increased thrombin generation 
and activation of blood fibrinolytic activity are noted. Against the background of treatment in the 1st group, platelet aggregation tends to 
normalize and there are significant differences compared with the indicators before treatment in the 1st group, the vascular-platelet and 
fibrinolytic systems did not reach normal values before 7 days, but showed a significant downward trend the degree of manifestation of 
their violations. Against the background of treatment of the 2nd group, significant changes were observed towards normalization in all 
components of the hemostatic system according to the LPTEG technique. The state of the coagulation unit of the hemostasis system in 
patients with OA on the 7th day of therapy does not significantly differ from the norm, it is possible to note significant shifts towards 
hypocoagulation within the normal range. The fibrinolytic system on the 7th day of treatment does not statistically differ from normal 
indicators, it has significant positive dynamics compared to 1 day. The second group revealed a statistically significant normalization of 
all indicators characterizing the blood coagulation potential of the blood and the aggregation ability of platelets, as well as the indicator 
that is responsible for changes in the fibrinolytic blood system.









About 2–3 % of the population and about 35–50 % of people over 65 years suffer from 
obliterating atherosclerosis of the main arteries of the lower extremities [1, 2]. The problem of 
treatment of obliterative atherosclerosis (OA) of the vessels of the lower extremities is currently 
very relevant [3]. There are many known factors that potentiate atherosclerosis [4]. Some of them 
are referred to as leading, such as hyperlipoproteinemia or hypertension, others to concomitant 
contributing to the defeat of the arteries [5, 6].
In addition, many researchers emphasize the poly factor of the process of atherogenesis, 
including the adverse effect of hemodynamic factors on the arterial wall, vasoactive substances, 
endo- and exogenous chemical compounds, dyslipoproteinemia of atherogenic nature, other dis-
orders [7, 8]. Special attention is paid to the role of early metabolic disorders of the arterial wall 
structure and the importance of lipoprotein oxidation in it [9, 10].
The association of an increased level of a number of factors of the hemostasis system with 
the development of atherosclerosis and its complications such as stroke and myocardial infarction 
has been demonstrated in a number of epidemiological studies [11, 12]. In hyperlipidemia, in ad-
dition to the increase in platelet activity, there is a decrease in antithrombogenic (antiaggregation, 
anticoagulant, fibrinolytic) activity of the vessel wall, increase in factor VII, fibrinogen, Villebrand 
factor and plasminogen activator inhibitor [13, 14]. According to J.S.A. Fuchs include hyperten-
sion, hypercholesterolemia and smoking as major risk factors for atherosclerosis [15]. They are less 
affected by obesity, diabetes, hypertriglyceridemia, sedentary lifestyle, stress [16]. Increased mor-
tality is mainly driven by a higher cardiovascular disease risk and reflects the underlying systemic 
atherosclerosis process in peripheral arterial disease patients [17]. 
 Increase in the concentration of Willibrand factor in the blood is a marker of endothelial 
damage and dysfunction, its increase is associated with the risk of vascular complications in pa-
tients with disorders of lipid metabolism [18,19]. Damage to the atherosclerotic plaque is a major 
link in further thrombogenesis. The lipid-rich plaque contains a tissue factor that locally initiates 
activation of the coagulation system [20, 21]. It is widely acknowledged that anticoagulant medica-
tion therapy is an integral part of the prevention of cardiovascular mortality and morbidity in this 
category of patients [22].
The aim of the study. The purpose of this study is to evaluate the functional state of the 
vascular – platelet, coagulation unit and fibrinolysis of the hemostasis system and their disorders by 
means of low – frequency piezoelectric thromboelastography (LPTEG) in patients with obliterating 
atherosclerosis of the lower extremities.
2. Materials and methods
Clinical material for the study is presented by 90 patients who have undergone treatment for 
obliterating atherosclerosis (OA) in the period from 2017 to 2019 on the basis of the departments 
of surgery and intensive care of the Odessa Regional Clinical Hospital. The criteria for inclusion 
in the study were: the presence of a patient with obliterating atherosclerosis (OA) IIb and III stage, 
verified by computer angiography or Doppler ultrasound, stenosis of the femoral, popliteal or tibial 
segment, age 18 years or older, the absence of factors indicated exclusion criteria, informed written 
consent of the patient to participate in the study. Exclusion criteria for the study were: refusal of the 
patient to participate in the study, refusal of patients from the components of therapy: transfusion 
of blood components (for religious reasons), epidural anesthesia and analgesia (fear of complica-
tions of puncture of the epidural space), the presence of relative or absolute opposite the presence 
of allergic reactions to lidocaine or bupivacaine, uncompensated chronic diseases or diseases that 
affect the hemostatic system. 
The study is in compliance with the legislation of Ukraine on medical ethics and was ap-
proved at the meeting of the Commission on Bioethics of the Odessa National Medical University 
(protocol No. 147 B of May 21, 2017).
All patients provided informed written consent to participate in the study.
Evaluation of the hemostasis system was carried out using LPTEG. Blood sampling for the 
study was performed under the same conditions according to the standard method from cubital vein 
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of the subjects. To study the system of hemostasis and rheological properties of blood, hardware 
and software complex ARP-01M «Mednord» was used for continuous registration of the basic pa-
rameters of the process of blood clot formation and its lysis.
All patients underwent surgical intervention in the volume of the hip-hamstring bypass with 
an auto vein. Adding a patient with OA to a particular group occurred randomly. Patients of both 
groups were examined in the same way, received the same intensive care regimen, indications for 
surgical intervention were set on the basis of the same criteria. Patients in the control (1st) group  
(45 patients) received analgesia during surgery and in the postoperative period based on epidural ad-
ministration of bupivacaine, and their treatment regimen included enoxaparin 0.4 ml (40 000 anti-XA 
ME) 2 times a day subcutaneously into the anterolateral surface of the abdominal wall from the first 
postoperative day and pentoxifylline into vein 200 mg twice a day for 7 days. Patients of the studied 
(2nd) group (45 patients) received analgesia during surgery and in the postoperative period on the 
basis of epidural administration of bupivacaine, also rivaroxaban 15 mg 2 times a day oraly on the 
first postoperative day and pentoxifylline into vein 200 mg twice a day for 7 days was included in 
their treatment regimen. The group of healthy volunteers consisted of 45 people, aged 45 to 65 years, 
undergoing a planned annual medical examination and not having any pathology.
The dynamics of the state of the hemostatic system in both groups of patients with OA was 
evaluated using LPTEG in the first day before surgery and on the 3rd, 5th and 7th postoperative 
days. OA treatment included gastroprotective, rheologically, antioxidant, metabolic and infusion 
therapy.
Statistical processing of the obtained results was performed using the formulas known in 
medical statistics and consisted of determination of average values   of numerical characteristics of 
the studied process, numerical characteristics of the degree of process variability, estimation of 
confidence interval and significance level, correlation analysis and determination of correlation 
reliability. Most of the numerical data obtained from the study were subjected to statistical analysis 
using the Student’s t test with the calculation of arithmetic mean (M), root mean square deviation 
(δ), criterion for reliability of difference of mean values   (t). Differences were considered significant 
if p is less than 0.05, which corresponds to 95 % and is more likely to make an error. The results of 
the study were mathematically processed after the database was created on the Microsoft system 
using a suite of programs integrated into the Microsoft Office system using the Student’s t test.
3. Results
In patients with OA, a significant structural (increase in the amplitude of the maximum 
density of the clot (MA LPTEG)) and chronometric (reduction of the intensity of the contact phase 
of coagulation (ICC), the intensity of coagulation drive (the intensity of clot formation (ICD), a 
constant thrombin activity (CTA) and blood clotting time (BCT(t3)) of LPTEG) hypercoagulation 
with increased thrombin generation (initial rate of aggregation of blood at the time t0 (A0), the time 
the contact phase of coagulation (R(t1)), the clot intensity of the polymerization (CIP LPTEG)) and 
depression of fibrinolysis – the intensity of the retraction and clot lysis (IRCL).
After surgery according to LPTEG (Table 1) in the first group, changes in indicators to-
ward hypercoagulation were established: in patients with OA, numerous structural (increase in 
MA) and chronometric (reduction of ICC, CTA and ICD, BCT reduction were noted in patients 
with OA, hypercoagulation with increased thrombin activity (A0, R (t1), ICC) and depression 
of fibrinolysis (IRCL).
The recorded amplitude of the indicator of the intensity of the contact phase coagula-
tion (ICC) 145,41±3,23 r.u. (in the 1st group), at the rate of 84.3±10.91 r.u., the initial indicator of 
the aggregate state of blood at the time of AO 435,49±26,88 r.u. (in the 1st group), at the rate of 
222.25±15.33 r.u., the coagulation contact phase time R (t1) is 1.36±0.34 minutes (in the 1st group) 
at a rate of 2.36±0.34, all of which indicates an increase in spontaneous platelet aggregation. An 
increase in the amplitude and shortening of the time constants of hemocoagulation were also noted. 
When comparing the results with the healthy group, the following data were obtained: an increase 
in the constant thrombin activity (CTA) by 104 % in the first group, an increase in the blood clot-
ting time (BCT (t3)) by 47.26 % in the first group, an increase in the intensity of coagulation drive 
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(ICD) by 97.3 % in the first group, an increase in maximal density of the clot (MA) by 74.03 % in 
the first group, an decrease in the rate of retraction and clot lysis (IRCL) by 47.29 % in the first. 
In the second group, similar changes were observed before the start of treatment compared to the 
group of healthy volunteers. Thus, the A0 increased by 88.81 %, the R (t1) increased by 40.38 %, the 
CTA increased by 97.89 % compared to the norm. The MA indicator in the second group increased 
by 57.16 % compared to the indicator of healthy volunteers (825.81±51.87 r.u. vs. 525.45±60.50). In 
the second group, the activation of the fibrinolysis system was observed, an decrease in IRCL by 
39.33 % compared to the norm.
Table 1
The state of hemostasis in patients with OA before treatment (M±m)
No. Іndicator Healthy group 1(st) group 2(nd) group
1 А0 222.25±15.33 435.49±26.88* 419.65±23.12*
2 R(t1) 2.36±0.34 1.36±0.34* 1.48±0.11*
3 ICC 84.3±10.91 145.41±3.23* 139.74±3.03*
4 CTA 15.22±3.46 31.13±0.54* 30.12±0.51*
5 BCT(t3) 8.42±1.68 4.44±0.39* 5.02±0.29*
6 ICD 21.15±3.70 41.73±1.29* 37.59±0.93*
7 CIP 14.45±1.4 31.47±0.87* 28.43±0.25*
8 МА 525.45±60.50 914.49±61.13* 825.81±51.87*
9 IRCL 16.45±1.40 8.67±0.66* 9.98±0.59*
Note: differences are significant in comparison with the healthy group, * – p<0.05
On the third day after surgery in both groups, we observed statistically significant (p<0.05) 
changes towards hypercoagulation with moderate dynamics toward normalization. Thus, the pres-
ervation of activation of the platelet component of hemostasis was indicated by an increase in the 
degree of A0 by 88.81 % in the 1st group and 46.42 % in the 2nd group; R (t1) was 37.28 % in group 1 
and 10.16 % in group 2, and there was also a change in ICC of 65, 76 % in group 1 and 18.23 % in 
group 2 in compared to healthy volunteers.
A statistically significant deviation from the norm of LTPEG indices was revealed (Table 2), 
namely A0, R (t1) and ICC, which characterize platelet aggregation capacity. Thus, the registered 
amplitude of the indicator of the intensity of the contact phase of coagulation (ICC) 139.74±3.03 r.u. in 
group 1 and 119.23±1.78 r.u. in group 2, at a rate of 84.3±10.91 r.u., the initial indicator of the aggregate 
state of blood at time A0 419.65±23,12 r.u. in 1 group and 325.44±22.34 r.u. in group 2, at the rate of 
222.25±15.33 r.u., the contact phase of coagulation time (R (t1)) is 1.48±0.11 minutes in group 1 and 
2.03±0.18 minutes in group 2, with a rate of 2.36±0.34, all of which indicates a significant increase 
spontaneous platelet aggregation. An increase in the amplitude and shortening of the time constants 
of hemocoagulation were also noted. When comparing the results with the healthy group, the fol-
lowing data were obtained: an increase in the constant of thrombin activity (CTA) by 97.89 % in the 
1st group and by 80.74 % in the 2nd group, a decrease in the blood clotting time (T3) by 40 , 38 % in 
Group 1 and 21.73 % in Group 2, the intensity of coagulation drive (ICD) accelerated by 77.73 % in 
Group 1 and 54.04 % in Group 2, increasing the maximum density of the clot was 57.16 % in Group 
1 and 33.1 % in Group 2. The nature of the changes indicates the presence of hypercoagulation due 
to increased activity and vascular-platelet and procoagulant hemostasis, as well as deviation from the 
norm, which characterizes fibrinolytic activity (IRCL) decrease by 39.33 % in the 1st group and by 
33.09 % in 2nd group compared to healthy volunteers.
These changes in the hemostasis system indicate a decrease in hypercoagulation, hyperag-
gregation with the orientation of both groups toward normocoagulation, which are more significant 
in the second group, which we believe is associated with the use of rivaroxaban as a component of 
treatment in patients of the second group.
Fig. 1 shows the indicators of LPTEG on day 3 in both groups and in healthy volunteers. 
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State of hemostasis system in patients with OA for 3 days after surgery (M±m)
No. Іndicator Healthy group 1(st) group 2(nd) group
1 А0 222.25±15.33 419.65±23.12* 325.44±22.34*
2 R(t1) 2.36±0.34 1.48±0.11* 2.03±0.18*
3 ICC 84.3±10.91 139.74±3.03* 119.23±1.78*
4 CTA 15.22±3.46 30.12±0.51*× 27.51±0.53*
5 BCT(t3) 8.42±1.68 5.02±0.29* 6.59±0.31*
6 ICD 21.15±3.70 37.59±0.93*× 32.58±1.21*
7 CIP 14.45±1.4 28.43±0.25*× 22.81±0.49*
8 МА 525.45±60.50 825.81±51.87* 699.67±39.58*
9 IRCL 16.45±1.40 9.98±0.59* 11.02±0.44*
Note: the differences are significant compared to the healthy group, * – p<0.05.
Fig. 1. Idicators of LPTEG on day 3 in both groups and in healthy volunteers
On day 5, according to the LPTEG (Table 3), the first group revealed statistically unre-
liable deviations from the indicators of healthy volunteers: indicators A0, R (t1) and ICC, which 
characterize the aggregation capacity of platelets, and the indicators that characterize hemo-
coagulation potential CTA, ICD, CIP, BCT as well as the indicator responsible for changes in 
the fibrinolytic blood system (IRCL). In the second group, these indicators are almost indistin-
guishable from those of the norm, indicating a more substantial change towards normalization in 
patients of the second group.
Table 3
Condition of hemostasis system in patients with OA for 5 days after surgery (M±m)
No. Іndicator Healthy group 1(st) group 2(nd) group
1 А0 222.25±15.33 402.51±19.51* 259.49±19.87*
2 R(t1) 2.36±0.34 2.02±0.17* 2.12±0.18*
3 ICC 84.3±10.91 127.84±1.96* 99.67± 2.02*
4 CTA 15.22±3.46 26.49±1.36* 16.31± 0.50*
5 BCT(t3) 8.42±1.68 6.04±0.43* 8.08±0.23 *
6 ICD 21.15±3.70 32.44±0.84* 22.41±1.02*
7 CIP 14.45±1.4 21.54±0.48* 15.45±0.51*
8 МА 525.45±60.50 759.47±39.34* 576.48±22.71*
9 IRCL 16.45±1.40 12.22±0.56* 15.44±0.37*






















The registered value of the intensity of the contact phase of coagulation (ICC) 127.84± 
±1.96 r.u. (in the 1st group), at the rate of 84.3±10.91 r.u., initial rate of aggregation of blood at the 
time t0 402.51±19.51 r.u. (in the 1st group), at the rate of 222.25±15.33 r.u., the contact phase coag-
ulation phase R (t1) 2.02±0.17 minutes (in the 1st group) at the rate of 2.36±0.34, all this indicates 
the preservation of hyperagregation against the background of the trend towards normalization in 
patients the first group. Changes in the amplitude and time constants of hemocoagulation were also 
observed. When comparing the results with the healthy group, the following data were obtained: 
constant thrombin activity (CTA) was greater by 74.04 % in the first group, decrease in blood 
clotting time (T3) changed by 28.02 % in the first group, the intensity of coagulation drive ICD 
by 53.38 % in the first group, maximum density of the clot of MA by 44.53 % in the first group, 
intensity of retraction and clot lysis (IRCL) by 25.71 % in the first.
In the second group statistically significant changes towards normalization of indicators 
with preservation of moderate hypercoagulation were revealed: indicators characterizing hemoco-
agulation potential of blood CTA, BCT, ICD, CIP, MA and indicators A0, R (t1) and ICC, which 
characterize the aggregation capacity of platelets as well as the indicator responsible for changes in 
the fibrinolytic blood system. The recorded amplitude of the indicator of the intensity of the contact 
phase of coagulation (ICC) 99.67±2.02 r.u. (in the 2nd group), at the rate of 84.3±10.91 r.u., the ini-
tial indicator of the aggregate state of blood at the time of AO 259.49±19.87 r.u. (in the 2nd group), 
at the rate of 222.25±15.33 r.u., the contact phase coagulation R (t1) 2.12±0.18 minutes (in the 
2nd group) at the rate of 2.36±0.34, all this indicates a significant (p<0.05) increase in spontaneous 
platelet aggregation. Also observed is the increase in the amplitude and the reduction of the time 
constants of hemocoagulation. When comparing the results with the healthy group, the following 
data were obtained: an increase in CT by 7.16 % in the second group of patients, an increase in the 
clotting time of CSF blood (t3) by 4.03 %, an increase in ICD by 5.95 % and an increase in MA 
by 9.71 %. The above changes indicate that patients in the second group show a marked tendency 
toward normalization of all parameters of the hemostasis system, while maintaining a slight hy-
po-coagulation, hyperaggregation and depression of fibrinolysis.
Fig. 2 shows the indicators of LPTEG on day 5 in both groups and in healthy volunteers. 
Fig. 2. Indicators of LPTEG on day 5 in both groups and in healthy volunteers
On day 7, according to the LTPEG (Table 4), in the first group, statistically significant de-
viation from the norm of indicators towards moderate hypercoagulation was revealed: indicators 
A0, R (t1) and ICC, which characterize the aggregation capacity of platelets and the indicators that 
characterize hemocoagulation, ICD, CIP, MA well as the indicator responsible for changes in the 
fibrinolytic blood system. In patients of the second group normalization of all indicators of the 
hemostasis system is noted.
The recorded amplitude of the coagulation contact phase (ICC) intensity index is 114.74± 
±1.78 r.u. (in the 1st group), at the rate of 84.3±10.91 r.u., the initial indicator of the aggregate state 
of blood at A0 365.46±19.65 r.u. (in the 1st group), at the rate of 222.25±15.33 r.u., the contact phase 





















indicates the preservation of activation of spontaneous platelet aggregation. Consideration was also 
given to increasing the amplitude and reducing the time constants of hemocoagulation in patients 
of the first group compared with the group of healthy volunteers. When comparing the results with 
the healthy group, the following data were obtained: an increase in constant thrombin activity 
(CTA) by 9.59 % in the first group, a reduction in blood clotting time (t3) by 4.51 % in the first 
group, an increase in the intensity of coagulation drive ICD by 3.26 % in the first group, increase 
in maximal density of the clot MA by 15.2 % in the first group, depression of the intensity of the 
retraction and clot lysis (IRCL) by 20.18 % in the first.
Table 4
The state of hemostasis in patients with OA for 7 days after surgery (M±m)
No. Іndicator Healthy group 1(st) group 2(nd) group
1 А0 222.25±15.33 365.46±19.65* 220.43±15.61*
2 R(t1) 2.36±0.34 2.19±0.08* 2.37±0.15*
3 ICC 84.3±10.91 114.74±1.78* 84.41±1.61*
4 CTA 15.22±3.46 16.68±0.41* 15.16±0.56*
5 BCT(t3) 8.42±1.68 8.04±0.31* 8.49±0.18*
6 ICD 21.15±3.70 21.84±0.58* 20.48±0.87*
7 CIP 14.45±1.4 14.74±0.67* 14.21±0.47*
8 МА 525.45±60.50 605.36±29.47* 529.49±31.65*
9 IRCL 16.45±1.40 13.13±0.63* 16.39±0.36*
Note: differences are significant in comparison with the healthy group, * – p<0.05
In the second group, statistically significant (p<0.05) normalization of all indicators charac-
terizing hemocoagulation potential of blood CTA, BCT, ICD, CIP, MA and indicators A0, R (t1) and 
ICCcharacterizing platelet aggregation capacity, as well as an indicator responsible for changes in the 
fibrinolytic blood system. The recorded amplitude of the indicator of the intensity of the contact phase 
coagulation (ICC) 84.41±1.61 r.u. (in the 2nd group), at the rate of 84.3±10.91 r.u., the initial rate of ag-
gregation of blood at the time of A0 220.43±15.61 r.u. (in the 2nd group), at the rate of 222.25±15.33 r.u., 
the coagulation contact phase time R (t1) is 2.37±0.15 minutes (in the 2nd group) at the rate of 2.36±0.34, 
all of which indicates a reliable normalization of these parameters. Normalization of the amplitude and 
time constants of hemocoagulation is also noted. The nature of the thromboelastogram indicates the 
normalization of all hemostatic system on the background of treatment on the 7th day after surgery.
Fig. 3 shows the indicators of LPTEG on day 7 in both groups and in healthy volunteers. 
Fig. 4 shows the dynamics of A0 LPTEG in both groups. Fig. 5 shows the dynamics of ICC LPTEG 
in both groups. Fig. 6 shows the dynamics of ICD LPTEG in both groups. Fig. 7 shows the dynam-
ics of MA LPTEG in both groups.




















Fig. 4. Dynamics of A0 LPTEG in both groups 
Fig. 5. Dynamics of ICC LPTEG in both groups 
Fig. 6. Dynamics of ICD LPTEG in both groups 

































































Analysis of the hemostasis system in patients with OA using NPTEG in dynamics shows the 
possibility of using the NPTEG method for early diagnosis of the degree of hemostasis disorders 
and control of anticoagulant therapy.
From the above figures and tables, we can see that the differential correction of hemostat-
ic system disorders, namely the use of rivaroxoban in the postoperative period and the NTPEG 
method, contributed to the improvement of the coagulation and fibrinolytic units of the hemostasis 
system at all stages of surgical treatment. Rivaroxaban as a new anticoagulant is now gaining pop-
ularity thanks to a safer use profile. 
The effect of rivaroxaban on different categories of patients and in combination with differ-
ent drugs is now widely studied.
Comparing our data with the COMPASS study [23], we can state the effectiveness of the 
use of rivaroxoban for the treatment and prevention of thromboembolic events in this category of 
patients. According to the COMPASS study, the success of rivaroxban for the prevention of sec-
ondary cardiovascular events is shown. The final results show that the combination of rivaroxaban 
plus aspirin was associated with a significantly smaller number of events of the primary outcome, 
compared with taking aspirin alone, including patients with obliterating atherosclerosis.
Continuing this study, it is possible to study the feasibility of prolonged use of rivaroxaban 
in this category of patients with the goal of preventing retrombosis in the area of shunt.
Limitations of the study: the limitations of this study is the impossibility of conducting a 
study in patients previously taking anticoagulants for concomitant pathology.
In the future prospect of further research, we hope to show the most rational scheme for the 
prevention of thromboembolic events in this category of patients. Also, we want to demonstrate the 
possibilities of using LFTEG to monitor the state of the hemostatic system during treatment and in 
order to further control the dosage.
5. Conclusions
Significant structural and chronometric hypercoagulation with increased thrombin genera-
tion and inhibition of fibrinolytic activity of blood was noted before surgery and the beginning of 
treatment in patients with OA on the background of activation of the vascular-platelet hemostasis.
Against the background of treatment in group 1, the complex of the epidural administration 
of bupivacaine, enoxaparin 0.4 ml (40,000 anti-HA MO) 2 times a day from the first postoperative 
day and pentoxifylline IV 200 mg twice a day were observed reliable changes toward normaliza-
tion in all components of the hemostasis system according to the NTPEG method (p<0.001). The 
fibrinolytic system in group 1 was suppressed at day 7 of treatment (p<0.001) compared to normal 
but has positive dynamics compared to day 1 (p<0.001). Platelet aggregation is increased compared 
to the norm (p<0.001) and has significant (p<0.001) differences compared with the indicators be-
fore treatment in group 1. Intensive care of group 1 on the background of systemic pathological 
process led to normalization of the coagulation link of the hemostasis system in patients with OA. 
Vascular-platelet and fibrinolytic systems did not reach normal values  in 7 days, but showed a sig-
nificant tendency to decrease the degree of manifestations of their disorders (p<0.001).
On the background of treatment of the 2nd group in the composition of the epidural ad-
ministration of bupivacaine, rivaroxaban 15 mg 2 times daily orally from the first postoperative 
day, significant changes towards normalization were observed in all components of the hemostasis 
system by the method of LPTEG (p<0.001). The state of the coagulation unit of the hemostasis 
system in patients with OA for 7 days of therapy does not differ significantly from the indicators 
of the norm, it is possible to note significant shifts to hypocoagulation within the norm (p<0.05). 
The fibrinolytic system at the 7th day of treatment is not statistically different from the norms, 
has a positive dynamics compared to 1 day (p<0.001). Platelet aggregation is also not statistically 
different from normal values  and has significant differences compared with rates of 5 and 1 day 
(p<0.05; p<0.001).
In the second group, statistically significant (p<0.05) normalization of all indicators that 
characterize the hemocoagulation potential of blood CTA, BCT, CIP, ICD, MA and indicators A0, 
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R (t1) and ICC, which characterize the aggregation capacity of platelets, were found. as well as the 
indicator responsible for changes in the fibrinolytic blood system.
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Abstract
The aim of the research. Development and implementation of new methods for pre-operative staging of advanced ovarian, gas-
tric and colorectal cancer to improve patient selection for cytoreductive surgery and increase its radicality.
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